- Forum gebruiker
- Berichten: 143
- Lid geworden op: 26 Jun 2015 14:38
- waarderingen: 48
mijn gemiddelde is nu wel serieus gezakt sta nu op 4.19 $
- Forum actieveling
- Berichten: 344
- Lid geworden op: 08 Aug 2018 18:39
- waarderingen: 127
$TXMD WOW! Imvexxy grew 20% last week. Approx 10,500-11,500 scripts for last week. Looking like 35-40k for May. Best growth this whole year. If this pace stays around 10-15% you are looking at 75k scripts a month in 4th qtr. That brings in 15 plus million just in imvexxy rev.
Benieuwd wat maandag 10 juni zal brengen.
- Forum veteraan
- Berichten: 1106
- Lid geworden op: 13 Feb 2012 18:07
- waarderingen: 256
Volgende week 10 juni is er een presentatie gepland.
- Forum actieveling
- Berichten: 644
- Lid geworden op: 06 Sep 2018 20:48
- waarderingen: 251
Backerrr schreef:Verdorie toch.... bedankt Txmd voor de goede start van mijn paar dagen vakantie
Zal leuk dagje worden ja. Verliezen van afgelopen weken wegwerken...
- Lama Daila
- Forum veteraan
- Berichten: 1813
- Lid geworden op: 20 Jul 2017 10:53
- waarderingen: 3164
TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States
-Agreement leverages Theramex’s extensive women’s health capabilities and infrastructure to the benefit of menopausal women outside of U.S.-
-TherapeuticsMD to receive EUR 14 million as an upfront fee and is eligible to receive up to EUR 29.5 million in regulatory and sales milestone payments, as well as a royalty on net sales-
BOCA RATON, Fla.--(BUSINESS WIRE)--Jun. 7, 2019-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it has entered into an exclusive license and supply agreement with Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the United States. Theramex is a portfolio company of CVC Capital Partners.
Theramex will have exclusive commercialization rights for BIJUVA and IMVEXXY outside the U.S., excluding Canada and Israel, for which TherapeuticsMD has licensed BIJUVA and IMVEXXY to Knight Therapeutics. Theramex will be responsible for conducting all regulatory and commercial activities in connection with BIJUVA and IMVEXXY in the licensed territories.
Under the terms of the license and supply agreement, Theramex will pay TherapeuticsMD EUR 14 million in cash as an upfront fee. TherapeuticsMD is eligible to receive up to an additional EUR 29.5 million in cash milestone payments, comprised of (i) an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets and (ii) an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on first attaining certain aggregate annual net sales milestones in the licensed territories ranging from EUR 25 million to EUR 100 million. TherapeuticsMD is also entitled to receive royalty payments on net sales of BIJUVA and IMVEXXY in the licensed territories.
"We are very pleased to announce our partnership with Theramex to bring BIJUVA and IMVEXXY to women outside of the United States,” said Robert G. Finizio, CEO of TherapeuticsMD. “We believe this agreement provides our company with important non-dilutive upfront capital to help fund our product launches in the United States as well as an incremental royalty stream to support future growth.”
Anish Mehta, CEO of Theramex, said, “This partnership with TherapeuticsMD marks another exciting milestone in the execution of our women’s health growth strategy. By leveraging our best in class commercial capabilities and global footprint, we intend to rapidly commercialize these novel and innovative medicines for women around the world.”
“BIJUVA and IMVEXXY strengthens Theramex’s already exciting range of women’s health treatment options for doctors and their patients,” said Fred Hassan, Chairman of Theramex.
Deelnemen aan het forum + meer functies?
Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen enkele tellen